Genmab — November 2019
-
det virker lidt underligt, er da ret så betydeligt, men åbenbart ikke nok til en fondsbørsmeddelse
-
innovaTV 208 adds an extra trial arm, 40 more patients, and is extended by 1 year https://clinicaltrials.gov/ct2/history/NCT03657043?A=15&B=16&C=merged#StudyPageTop
-
the Dara atezolizumab NSCLC trial set to completed
https://clinicaltrials.gov/ct2/history/NCT03023423?A=28&B=29&C=merged#StudyPageTop -
-
-
De skriver sådan set i introduktionen til Candor abs, hvorfor det er vigtigt: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these agents or discontinue them due to toxicity. There is a need for novel, efficacious, and tolerable regimens that can treat MM pts who are exposed or refractory to LEN or BTZ.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind